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Original Article
introDuCtion
Asthma is a chronic airway disease characterized by reversible 
airflow obstruction and airway hyperresponsiveness, 
increased expression of numerous cytokines, chemokines, 
and other inflammatory mediators which possibly contribute 
to infiltrating inflammatory cells and remodeling in the 
airways.[1,2] Although increased evidence have implicated 
that asthma is a Th2‑type inflammatory disorder,[1,2] 
other mediators including proinflammatory cytokines 
interleukin‑1 (IL‑1), IL‑6, IL‑17, and tumor necrosis 
factor‑alpha (TNF‑α) and various chemokines such as 
CXC and CC chemokines CXCL8, CXCL10, CCL2, CCL4, 
CCL11, and others may also participate in the pathogenesis 
of asthma, through acting directly or indirectly on the target 
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Background: Increased proinflammatory cytokines and chemokines might contribute to infiltration of inflammatory cells and remodeling 
in airways of asthma. Although these molecules may be associated with asthma, there is lack of systemic evidence showing which and 
how important these events are in the disease. We aimed to analyze the concentrations of these molecules in the airways and relationships 
with disease severity and with airway infiltration of inflammatory cells in a large cohort of asthmatics (n = 70, including 37 mild and 
33 moderate/severe asthmatics) compared with controls (n = 30).
Methods: Meso scale discovery system and commercial ELISA kits were used to measure the concentrations of proinflammatory cytokines 
interleukin (IL)‑1β; tumor necrosis factor‑alpha (TNF‑α); IL‑6; and IL‑17 and CC and CXC chemokines CCL2, CCL4, CCL11, CCL13, 
CCL17, CCL22, and CCL26 and CXCL8, CXCL9, CXCL10, and CXCL11 in bronchoalveolar lavage fluid of asthmatics and controls.
Results: The concentrations of IL‑1, TNF‑α, IL‑6, CXCL8 and CXCL10, and CCL4, CCL11, CCL17, and CCL22 were significantly elevated 
in asthmatics compared with controls (P < 0.05). The concentrations of TNF‑α and CXCL8, but not others, were negatively correlated with 
severity of disease (lung function forced expiratory volume in 1 s) (TNF‑α vs. total: r = −0.359, P = 0.002 vs. moderate/severe: r = −0.541, 
P = 0.001; CXCL8 vs. total: r = −0.327, P = 0.006 vs. moderate/severe: r = −0.625, P = 0.0001, respectively). In addition, concentrations 
of these two molecules were also correlated with the absolute numbers of infiltrating eosinophils and neutrophils in asthmatic airways.
Conclusions: Increased concentrations of TNF‑α and CXCL8 are associated with pathogenesis of asthma. Targeting these molecules 
might provide an alternative therapeutic for this disease.
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cells.[1‑4] Increased expression of these proinflammatory 
cytokines and various chemokines, at mRNA or protein 
levels, is observed in different clinical samples of asthmatics 
compared with controls, such as peripheral blood, sputum, 
bronchoalveolar lavage fluid (BALF), and bronchial 
biopsies.[5‑8] However, these observations vary from 
individual studies and sometimes are even contradictory, 
possibly because of the limitation of numbers of subjects, 
different kinds of samples, and noncorrespondence between 
transcription and translation of certain molecules. In this 
case, little is known about the systemic evaluation of whether 
these proinflammatory cytokines and chemokines are all 
equally important and what is the associated status of other 
biomarkers in human asthmatic airways.
To address this, we have now measured the concentrations of 
proinflammatory cytokines TNF‑α, IL‑1β, IL‑6, and IL‑17 
and 11 CXC and CC chemokines in bronchial alveolar lavage 
fluid from a large cohort of 100 subjects (asthmatics = 70, 
including 37 mild and 33 moderate/severe asthmatics, and 
controls = 30). Chemokines whose concentrations were 
measured in the present study included CXCL8 (IL‑8), 
CXCL9 (monokine induced by gamma interferon), CXCL10 
(interferon‑gamma‑induced protein 10 [IP‑10]), CXCL11 
(interferon‑inducible T‑cell alpha chemoattractant), 
CCL4 (macrophage inflammatory protein 1β [MIP‑1β]), 
CCL11 (eotaxin‑1), CCL26 (eotaxin‑3), CCL17 (thymus 
and ac t ivat ion‑regula ted  chemokine  [TARC]) , 
CCL22 (macrophage‑derived chemokine [MDC]), CCL2 
(monocyte chemoattractant protein 1 [MCP‑1]), and 
CCL13 (MCP‑4). We hypothesized that the elevated 
expression of these cytokines and chemokines is 
associated with a degree which correlates with the 
accumulation of inflammatory cells, as well as lung function.
methoDs
Ethical approval
The protocol for this study was approved by the Ethics 
Committee of King’s College London Guy’s Hospital 
(LREC Reference Number: 07/H0804/77). Written informed 
consent was obtained from the parents of all infants before 
their inclusion in the study.
Subjects
One hundred subjects (70 asthmatics, including 37 patients 
with mild and 33 patients with moderate and/or severe asthma, 
and 30 normal controls) were defined according to the  Global 
INitiative for Asthma (GINA) guidelines[9] and recruited in 
the Department of Asthma, Allergy and Respiratory Science, 
King’s College London School of Medicine, UK. Asthmatics 
had a clear history of relevant symptoms, documented 
reversible airway obstruction (20% improvement in forced 
expiratory volume in 1 s (FEV1) either spontaneously or 
after administration of inhaled β2 agonist), and/or histamine 
provocation concentration causing a 20% fall in FEV1 (<8 mg/
ml) measured within 2 weeks before BAL. None of them had 
ever smoked, and there was no history of other respiratory 
diseases. All subjects were clinically free of respiratory 
infection and systemic glucocorticoid therapy for at least 
1 month before the study. Atopy was defined as a positive 
skin prick test (wheal at 15 min >3 mm in diameter in the 
presence of positive histamine and negative diluent controls) 
to one or more extracts of common local aeroallergens. Of the 
asthmatics, 63 of 70 were atopic. Of the controls, 4 of 30 were 
atopic. Normal controls were healthy, lifelong, nonsmoking 
volunteers who had no history of lung disease.
Fiberoptic bronchoscopy and bronchoalveolar lavage
The fiberoptic bronchoscopy procedure was performed 
as described previously.[10,11] The volume of fluid returned 
from BAL was measured. The BALF was passed through 
sterile gauze to remove any mucus. Supernatants were stored 
at −80°C until used. Cytospins were prepared from the cell 
pellets, and differential cell counts were performed with 
hematoxylin and eosin staining. The absolute numbers and 
percentages of eosinophils, neutrophils, lymphocytes, and 
monocyte/macrophages were quantified.
Analysis of proinflammatory cytokines and chemokines
Meso scale discovery (MSD) system (MSD, Rockville, 
MD, USA)[12] was used to measure the concentrations of 
proinflammatory cytokines and chemokines for IL‑1β, 
IL‑6, IL‑17, IL‑18, TNF‑α, CXCL8, CXCL10, CCL2, 
CCL4, CCL11, CCL13, CCL17, CCL22, and CCL26 
using a commercial kit (K15054G‑2). The concentrations 
of CXCL9 and CXCL11 in BALF were determined using 
commercial ELISA kits (R&D System, Inc., Minneapolis, 
MN, USA).[10]
Statistical analysis
Data were analyzed with the aid of a commercially available 
statistical package (Minitab for Windows Release 9.2; Minitab 
Inc., Coventry, UK). The Kruskal–Wallis analysis of variance 
and the Mann–Whitney U-test (with Bonferroni’s correction) 
were used for between‑ and within‑group comparisons, 
respectively. Correlation coefficients were obtained by 
Spearman’s rank‑order method with correction for tied values. 
For all tests, a P < 0.05 was considered significant.
results
Clinical data
The median  FEV 1 (percen t  p red ic ted)  o f  the 
asthmatics (median: 69.57%, range: 31.54–132.00) 
was significantly lower than that of the normal controls 
(median: 106.4%, 83.0–131.2%) (P < 0.0001). The clinical 
details are summarized in Table 1.
Inflammatory cellular infiltration
Although total cellular numbers in BALF were not 
significantly different between asthma and controls or 
between mild and moderate/severe asthmatics, the total 
numbers of neutrophils and eosinophils were significantly 
higher in asthma than those in controls (P < 0.05). 
Furthermore, total numbers of neutrophils in BALF from 
moderate/severe asthma were higher than those in mild 
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asthma and/or those in control (P < 0.0001) [Table 1]. In 
addition, both total numbers of neutrophils and eosinophils 
in BALF from asthmatics correlated inversely with FEV1 
(either of total asthmatics or of moderate/severe asthmatics: 
Total asthmatics – r = −0.56, P = 0.0001 for neutrophils, 
r = −0.258, P = 0.031 for eosinophils; moderate/severe 
asthmatics – r = −0.361, P = 0.04 for neutrophils, r = −0.43, 
P = 0.012 for eosinophils) (data not shown).
Concentrations of proinflammatory cytokines 
interleukin‑1, interleukin‑6, tumor necrosis factor‑α, 
and interleukin‑17 in bronchoalveolar lavage fluid
The median concentrations of IL‑1 were significantly 
elevated in BALF from subjects with asthma compared with 
controls (P < 0.0001). Furthermore, the concentrations of 
IL‑1 were significantly higher in mild and moderate/severe 
asthma than those of controls (P = 0.0007, P < 0.0001, 
respectively), although there was no significant difference 
in the median concentrations of IL‑1 between mild and 
moderate/severe asthmatics [Figure 1]. The median 
concentrations of TNF‑α significantly increased in 
the BALF of mild and moderate/severe asthmatics 
compared with those of controls (P = 0.0007, P < 0.0001, 
respectively) [Figure 1]. Furthermore, the median 
concentrations of TNF‑α were significantly greater in 
BALF from moderate/severe asthma than those of mild 
asthma (P = 0.0009) [Figure 1]. Similar patterns were 
also observed in the concentrations of IL‑6 in BALF. 
Figure 1: Concentrations of proinflammatory cytokines IL‑1, TNF‑α, IL‑6, and IL‑17 in BAL fluid from asthmatics (mild: n = 37, moderate/severe: 
n = 33) and controls (n = 30). Mann–Whitney U‑test. IL‑1: Interleukin‑1; TNF‑α: Tumor necrosis factor‑α; BAL: Bronchoalveolar lavage.
Table 1: Clinical information and cell counts
Asthma Controls
Mild Moderate/severe
Gender (female:male) 22:15 6:27 11:19
Age (years) 28 (21–57) 55 (29–73) 26 (19–69)
FEV1 (percent predicted)* 100 (81.6–133.0) 58.7 (31.5–69.76)
‡ 106.4 (80.0–131.2)
Total cell number (×106/ml) 1.8 (0.9–5.8) 2.3 (2.1–2.3) 1.6 (0.8–3.1)
Neutrophils* (×106/ml) 0.072 (0.0015–0.16) 0.0667‡ (0.017–0.135) 0.0147 (0.00–0.069)
Eosinophils* (×106/ml) 0.0589† (0.0–0.112) 0.0637† (0.0247–0.165) 0.00 (0.00–0.20)
Lymphocytes (×106/ml) 0.09 (0.03–1.11) 0.0923 (0.0305–0.254) 0.10 (0.0288–0.495)
Macrophage (×106/ml) 1.606 (0.797–5.46) 2.072 (0.757–3.029) 1.438 (0.74–2.83)
Data are expressed as the median (range). *Kruskal–Wallis test P<0.05 between asthma and control; †P<0.0001 versus controls; ‡Mann–Whitney U‑test 
and P<0.0001 (vs. mild and controls). FEV1: Forced expiratory volume in 1 s.
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The median concentrations of IL‑6 were significantly 
elevated in BALF of mild and moderate/severe asthma 
compared with those in controls (P = 0.0007, P < 0.0001, 
respectively) [Figure 1]. Again, the median concentrations 
of IL‑6 were greater in BALF of moderate/severe asthma 
than those in mild asthma (P = 0.0009) [Figure 1].
In contrast to these proinflammatory cytokines, there were 
no significant differences in the medians concentrations of 
IL‑17, either between controls and mild or moderate/severe 
asthma or between asthmatic subgroups [Figure 1], although 
the median concentrations of IL‑17 were significantly 
greater in BALF of total asthmatics compared with 
controls (P = 0.0291).
Concentrations of CXC chemokines CXCL8, CXCL9, 
CXCL10, and CXCL11 in bronchoalveolar lavage fluid
The median concentrations of CXCL8 (IL‑8) were 
significantly higher in BALF of mild and moderate/severe 
asthma compared with those of controls (P = 0.0009, 
P < 0.0001, respectively) [Figure 2]. In addition, the 
median concentrations of CXCL8 were significantly 
greater in BALF of moderate/severe asthma than those 
of mild asthma (P = 0.0021) [Figure 1]. The median 
concentrations of CXCL10 (IP‑10) were also significantly 
elevated in BALF of moderate/severe asthma compared 
with those of controls (P < 0.0001) and with those of 
mild asthma (P = 0.0007) [Figure 2]. However, there was 
no significant difference in the median concentration of 
CXCL10 in BALF between controls and mild asthma 
[Figure 1].
In contrast to CXCL8 and CXCL10, there were no significant 
differences in the median concentrations of CXCL9 and 
CXCL11, either between asthma and controls or between 
the subgroups of asthma [Figure 2].
Concentrations of CC chemokines CCL2, CCL4, CCL11, 
CCL13, CCL17, CCL22, and CCL26 in bronchoalveolar 
lavage fluid
The median concentrations CCL4 (MIP‑1β), CCL11 (eotaxin‑1), 
and CCL17 (TARC), but not CCL2 (MCP‑1), CCL13 (MCP‑4), 
CCL22 (MDC), and CCL26 (eotaxin‑3), were significantly 
greater in BALF from total asthmatics compared with 
controls (CCL4: P = 0.0001; CCL11: P = 0.0001; CCL17: 
P = 0.0008), while the median concentrations of CCL11, 
CCL17, CCL22, and CCL4 were significantly elevated 
in the BALF of mild asthma compared with those of 
controls (CCL11: P = 0.0074; CCL17: P = 0.0001; CCL22: 
P = 0.0125, CCL4: P = 0.0252, respectively) [Figures 3 and 4]. 
Furthermore, the median concentrations of CCL11 were 
significantly higher in BALF of moderate/severe asthma than 
those of mild asthma (CCL11: P = 0.0001) [Figures 3 and 4].
In contrast, there were no any significant differences in 
concentrations of CCL26, CCL2, and CCL13, either between 
total asthmatics and controls or between subgroups of 
asthma [Figures 3 and 4].
Figure 2: Concentrations of CXC motif chemokines CXCL8 (IL‑8), CXCL9 (Mig), CXCL10 (IP‑10), and CXCL11 (I‑TAC) in BAL fluid from 
asthmatics (mild: n = 37, moderate/severe: n = 33) and controls (n = 30). Mann–Whitney U‑test. IL‑8: Interleukin‑8; Mig: Monokine induced 
by gamma interferon; IP‑10: Interferon‑gamma‑induced protein 10; I‑TAC: Interferon‑inducible T‑cell alpha chemoattractant.
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Correlations of tumor necrosis factor‑α and CXCL8 
with lung function (forced expiratory volume in 1 s) and 
infiltrating inflammatory cells in the airways of asthma
Concentrations of TNF‑α and CXCL8, but not other 
proinflammatory cytokines or chemokines, correlated 
inversely with FEV1 of total asthmatics (TNF‑α: r = −0.359, 
P = 0.002; CXCL8: r = −0.327, P = 0.006) [Figure 5]. 
Furthermore, concentrations of TNF‑α and CXCL8 
also correlated inversely with lung function (FEV1) of 
moderate/severe asthmatics (TNF‑α: r = −0.541, P = 0.001; 
CXCL8: r = −0.625, P = 0.0001) [Figure 5]. Additionally, 
the concentrations of TNF‑α and CXCL8 also positively 
correlated with the absolute numbers of neutrophils and 
eosinophils of total asthmatics and of moderate/severe 
asthmatics (total TNF‑α vs. the numbers of neutrophils of total 
asthmatics: r = 0.243, P = 0.042; total TNF‑α vs. the numbers 
of eosinophils of total asthmatics: r = 0.311, P = 0.009; TNF‑α 
vs. the numbers of neutrophils of moderate/severe asthma: 
r = 0.379, P = 0.03; TNF‑α vs. the numbers of eosinophils 
of moderate/severe asthma: r = 0.565, P = 0.001; CXCL8 vs. 
the numbers of neutrophils of total asthmatics: r = 0.398, 
P = 0.001; CXCL8 vs. the numbers of eosinophils of total 
asthmatics: r = 0.331, P = 0.05; CXCL8 vs. the numbers of 
neutrophils of moderate/severe asthma: r = 0.499, P = 0.003; 
Figure 3: Concentrations of CC motif chemokines CCL11 (eotaxin), CCL26 (eotaxin‑3), CCL17 (TARC), and CCL22 (MDC) in BAL fluid from 
asthmatics (mild: n = 37, moderate/severe: n = 33) and controls (n = 30). Mann–Whitney U‑test. TARC: Thymus and activation‑regulated 
chemokine; MDC: Macrophage‑derived chemokine; BAL: Bronchoalveolar lavage.
Figure 4: Concentrations of CC motif chemokines CCL2 (MCP‑1), CCL13 (MCP‑4), and CCL4 (MIP‑1) in BAL fluid from asthmatics (mild: n = 37, 
moderate/severe: n = 33) and controls (n = 30). Mann–Whitney U‑test. MCP‑1: Monocyte chemoattractant protein 1; MIP‑1: Macrophage 
inflammatory protein 1; BAL: Bronchoalveolar lavage.
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CXCL8 vs. the numbers of eosinophils of moderate/severe 
asthma: r = 0.565, P = 0.001, respectively) (data not shown). 
Concentrations of IL‑1g (or IL‑1F4, IL‑18) were undetectable 
in BALF from all subjects.
DisCussion
Although it has been known that proinflammatory 
cytokines and chemokines also play an important role in the 
pathogenesis of asthma,[5‑8] there is still a lack of systemic 
comparison and evaluation of these molecules in the airways 
of asthma, possibly because of the investigators’ interesting 
and limitation of various sources of samples. For example, 
levels of these molecules in the peripheral blood might not 
always reflect the status of such targets in local airways,[13] 
while transcriptional results might not always equate to the 
status of translation. Here, we used BALF as a window 
to evaluate the concentrations of these proinflammatory 
cytokines and chemokines in a relatively large cohort of 
subjects with asthma and controls. We also tried to clarify 
the relationships of these molecules with the degree of 
disease severity and with infiltration of inflammatory cells 
in airways. Our data showed that the concentrations of 
proinflammatory cytokine TNF‑α and CXC motif CXCL8, 
but not others, were not only significantly elevated in BALF 
of asthmatics compared with controls, but also are inversely 
associated with lung function and positively correlated with 
local infiltration of neutrophils and eosinophils, suggesting 
the importance of these two molecules in the pathogenesis 
of asthma.
We had previously shown that TNF‑α mRNA‑positive 
cells were significantly elevated in the BALF of asthmatics 
compared with controls,[14] which was a first report regarding 
TNF‑α in asthma. Since that observation, numerous 
studies have shown that the concentrations of TNF‑α 
increase in BALF from subjects with asthma, including 
severe asthma.[15‑17] Our data here also showed that the 
concentrations of TNF‑α were greatly elevated in the 
BALF of asthmatics, accompanying with the association of 
lung function and airway inflammation, further confirming 
the findings of ours and others. Although the details of 
the roles of TNF‑α in the pathogenesis of asthma are 
still incompletely explored, it has been shown that this 
inflammatory cytokine might contribute to local recruitment 
of neutrophils and eosinophils, promoting the activation of 
T‑cells, inducing chronic airway remodeling and mediating 
steroid resistance.[18,19] Taken together, we conclude from this 
evidence that TNF‑α can be used as a therapeutic target in 
severe or steroid‑dependent asthma.[19,20]
Similar to TNF‑α, our data also showed that the concentrations 
of CXCL8, another name of IL‑8, increased in the BALF of 
asthmatics compared to controls and corresponded to the lung 
function and infiltration of neutrophils and eosinophils. It is 
worth to note that neutrophilia and increased concentration 
of IL‑8 have been considered as biomarkers in elderly and 
severe asthma.[13] Although IL‑8 is a relatively nonspecific 
chemokine for eosinophils, it has been shown that in 
the absence of eosinophil chemoattractants, neutrophils 
stimulated by IL‑8 augment eosinophil trans‑basement 
Figure 5: Correlations between FEV1 of total asthmatics and of moderate/severe asthmatics and concentrations of TNF‑α and CXCL8 (IL‑8). 
Correlation coefficients were obtained by Spearman’s rank‑order method with correction for tied values. FEV1: Forced expiratory volume in 1 s; 
TNF‑α: Tumor necrosis factor‑α; IL‑8: Interleukin‑8.
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membrane migration by releasing superoxide anion, matrix 
metalloproteinase, leukotriene B4, and platelet‑activating 
factor.[21] On the other hand, repeated recruitment of activated 
neutrophils might also contribute to allergic sensitization 
and airways inflammation.[22] These observations suggest 
that IL‑8‑stimulated neutrophils could lead eosinophils to 
accumulate in airways of asthmatics. We have currently 
showed that the concentration of IL‑8/CXCL8 in the 
BALF might be useful to distinguish uncontrolled asthma 
from total asthmatics.[23] It has recently shown that the oral 
administration of SCH 527123, a dual CXCR1/CXCR2 
antagonist, reduces neutrophil levels in the circulation 
and airways through inhibition of migration.[24] This may 
provide an alternative therapeutic for asthma, particularly 
for neutrophilic asthma.
Our data showed that another two proinflammatory cytokines 
IL‑1 and IL‑6 also significantly increased in the BALF of 
asthmatics compared with those of controls. Some studies 
implicate that the cytokines TNF‑α and IL‑8 together 
might be involved in Th17‑cell polarization or induce 
IL‑17 production.[25] It has been shown that IL‑17 might be 
relevant to severe asthma and steroid resistance of asthma; 
however, the concentration of IL‑17 in BALF appeared not 
to correspond to lung function or infiltration of neutrophils 
in the present study, although it was slightly higher in total 
asthmatics compared to the controls. Thus, importance of 
IL‑1 and IL‑6 in the pathogenesis of asthma remains to be 
explored,[26] at least when BALF is used as a window.
It has also been shown that CXC and CC chemokines may 
be involved in the pathogenesis of many diseases, including 
asthma, possibly through participating in the development 
and maintenance of innate and adaptive immunity, as well 
as in wound healing and angiogenesis.[27,28] We and others 
have previously reported that the expression of some CXC 
and CC cheomokines and their receptors are elevated in 
airways of asthma in a limited numbers of subjects.[10,29‑31] 
Thus, in the present study, we also analyzed a number of 
CXC and CC motif chemokines in the BALF of asthmatics 
and controls. Our data showed that the median concentrations 
of CXCL10 (IP‑10), CCL11 (eotaxin), CCL17 (TARC), and 
CCL4 (MIP‑1) were significantly elevated in the BALF 
of asthmatics compared with controls, with increases 
accompanying disease severity. However, such increased 
concentrations of these chemokines did not associate with 
lung function or with airway inflammation, suggesting that 
the increased expression of chemokines might not directly 
contribute to either impaired lung function or infiltration of 
inflammatory cells in the airways. In addition, the increased 
expression of these chemokines did not associate with the 
concentrations of any proinflammatory cytokines measured 
in the study, although these molecules might induce the 
expression of chemokines by airway structural cells or 
inflammatory cells in vitro or in vivo in animal models.[27,28]
In summary, correlations of proinflammatory cytokines 
TNF‑α and CXCL8 (IL‑8) and lung functions and 
infiltration of inflammatory cells including neutrophils and 
eosinophils further support that these molecules might be 
potential biomarkers and that targeting these molecules or 
their receptors might benefit asthmatic treatment, such as 
precision therapy.
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